Therapies for advanced cancerspose a special challenge for health technology assessment organizations in many countries
Health Affairs, 04/13/2012Neumann PJ et al.
In the United States, although no separate evaluation pathways exist for cancer, cancer drugs receive special status by virtue of unique Medicare rules covering off–label indications. Worldwide, authors demonstrate that health technology assessment organizations are struggling with cancer’s “exceptionalism.”
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.